Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($0.05) EPS. Wall Street Zen upgraded Ensysce Biosciences to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. Ensysce Biosciences Price PerformanceEnsysce Biosciences stock opened at $0.43 on Tuesday. Read MoreReceive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.